Development
Celldex ends barzolvolimab prurigo nodularis study after Phase II miss
Celldex Therapeutics (Hampton, New Jersey; Nasdaq: CLDX) reported topline results from a Phase II study of subcutaneous barzolvolimab in prurigo nodularis,...
Nuvation expands safusidenib program into post-vorasidenib IDH1-mutant glioma
Nuvation Bio Inc. (NYSE: NUVB) reported updated long-term data on Monday from the safusidenib clinical trial in IDH1-mutant glioma, alongside plans to...
Kolon's TG-C Phase III failure slows cell therapy push into knee osteoarthritis
Kolon TissueGene's first pivotal test of a cell and gene therapy for knee osteoarthritis has come back negative, complicating a development program that...
Pfizer ends development of Seagen-derived mesothelin ADC
Pfizer (NYSE: PFE), through its wholly owned subsidiary Seagen (Bothell, Washington), has discontinued clinical development of PF-08052666 (SGN-MesoC2,...
4DMT's 4D-150 extends durability to two years in wet AMD, challenging anti-VEGF injection dependence
4DMT's PRISM Phase IIb data support advancing 4D-150 through a broad wet AMD population, reinforcing the durability case for its lead gene therapy ahead of...
Regenxbio reports five-year durability for sura-vec ahead of pivotal wet AMD data ⭐
Regenxbio's ATMOSPHERE and ASCENT wet AMD trials—both pivotal, both fully enrolled—are set to read out topline efficacy data in the fourth quarter of 2026,...
Centauri launches first-in-human trial for dual-mechanism antibiotic
Centauri Therapeutics Limited has initiated a first-in-human clinical trial for CTX-187, a bifunctional antimicrobial designed to address...
Takeda showcases high-impact site efficacy for zasocitinib at AAD Innovation Academy
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) reported new secondary endpoint data from its two pivotal Phase III trials of zasocitinib...
K8's dual inflammasome inhibitor approach reshapes geographic atrophy treatment expectations
Inflammasome Therapeutics reported six-month Phase 2 results showing its investigational drug K8 slowed geographic atrophy lesion growth by more than half...
InnoCare advances soficitinib toward China filing after positive Phase III atopic dermatitis trial
InnoCare Pharma Limited (HKEX: 09969) announced on July 15 that soficitinib (ICP-332), its internally developed oral TYK2 inhibitor, met the primary...
GSK drops camlipixant after mixed Phase III results derail chronic cough program
GSK reported that its CALM-1 and CALM-2 phase III trials of camlipixant produced mixed results in refractory chronic cough (RCC), with one study meeting its...
BioNTech advances mRNA therapeutic HIV vaccine into randomized Phase I/II trial
BioNTech has registered a randomized, placebo-controlled Phase I/II clinical trial of BNT168, an mRNA vaccine designed to elicit HIV-specific immune...
Merck's Keytruda becomes first PD-1 inhibitor to beat chemotherapy in frontline dMMR endometrial cancer
Merck (NYSE: MRK) reported that pembrolizumab (Keytruda) monotherapy met its primary progression-free survival endpoint in the Phase III KEYNOTE-C93 trial,...
Allogene achieves first durable remissions with allogeneic CAR-T in solid tumors
Allogene Therapeutics (Nasdaq: ALLO) has published complete Phase I data from its TRAVERSE trial in the Journal of Clinical Oncology, reporting the first...
Ractigen's siRNA therapy RAG-17 shows deep SOD1 knockdown in first-in-human ALS trial
China-based Ractigen Therapeutics has published Phase I clinical data for RAG-17, an intrathecally delivered siRNA targeting SOD1 mRNA in patients with...
The AllSci Brief
Systematic R&D and deal news. Daily.